TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10193670
Drug: enalapril 20
Normalized name: enalapril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: enalapril 20 mg with propranolol 80 mg
Study: 10193670
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg alone
Study: 10193670
Drug: lisinopril 20
Normalized name: lisinopril 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: lisinopril 20 mg with propranolol 80 mg
Study: 28756267
Drug: Celecoxib 100
Normalized name: celecoxib 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 100 to 200 mg twice daily
Study: 28756267
Drug: Naproxen 375
Normalized name: naproxen 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen 375 to 500 mg twice daily
Study: 28756267
Drug: Ibuprofen 600
Normalized name: ibuprofen 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen 600 to 800 mg thrice daily
Study: 23114559
Drug: Intensive 12-week
Normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive 12-week strength-power training, twice a week, supervised by a physiotherapist
Study: 17259833
Drug: Single-dose sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose sodium phosphate (45 mL)
Study: 17259833
Drug: Double-dose sodium
Normalized name: nedocromil sodium Metered Dose Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-dose sodium phosphate (90 mL)
Study: 15177699
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment for 3 and 6 months
Study: 15177699
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment for 6 months
Study: 15177699
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 3 and 6 months
Study: 15177699
Drug: rhGH treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: rhGH treatment in the open-label phase
Study: 15177699
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment in the open-label phase
Study: 7999599
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment 50 micrograms/g twice daily
Study: 7999599
Drug: Coal tar
Normalized name: Coal Tar
DrugBank: Coal tar (DB11082)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coal tar solution BP 15% v/w in aqueous cream applied in the evening
Study: 7999599
Drug: Calcipotriol ointment
Normalized name: calcipotriol
DrugBank: Calcipotriol (DB02300)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcipotriol ointment and Coal tar solution
Study: 3263379
Drug: 2.5 mg
Normalized name: biotin 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5 mg prednisone
Study: 26367736
Drug: Silymarin plus
Normalized name: silymarin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Silymarin plus vitamin E (2 tablets per day) and hypocaloric diet (1520 kcal, 52% carbohydrates, 25% lipids, 23% proteins) for 3 months
Study: 23245336
Drug: Gemcitabine (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (1000 mg/m² on day 1) and Cisplatin (25 mg/m² on days 2 and 4) with regional hyperthermia (1 hour on days 2 and 4) biweekly for 4 months
Study: 19673597
Drug: Dicloxacillin (1.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dicloxacillin (1.0 g intravenous dose, 30 min prior to operation)
Study: 19673597
Drug: Placebo (saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (saline infusion, 30 min prior to operation)
Study: 12644419
Drug: 50 micro
Normalized name: Digoxin 250 microgram oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micro g fentanyl epidurally
Study: 12644419
Drug: 100 micro
Normalized name: Digoxin 100 microgram oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 micro g fentanyl epidurally
Study: 10690937
Drug: GHRH 50
Normalized name: GHRH(1-44)
Approvals — FDA: no, EMA: no, PMDA: no
Description: GHRH 50 microg intravenous (IV) injection
Study: 10690937
Drug: Porcine GAL
Normalized name: porcine gallbladder preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porcine GAL 500 microg infusion from -10 to +30 minutes
Study: 8456753
Drug: Hirulog 0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.05 mg/kg intravenous bolus followed by 0.2 mg/kg/hour intravenous infusion
Study: 8456753
Drug: Hirulog 0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hirulog 0.15 mg/kg intravenous bolus followed by 0.6 mg/kg/hour intravenous infusion
Study: 8456753
Drug: Heparin 5,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin 5,000 U intravenous bolus
Study: 20386216
Drug: Mini-implant anchorage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mini-implant anchorage
Study: 20386216
Drug: Molar anchorage
Normalized name: Polar Freeze
Approvals — FDA: no, EMA: no, PMDA: no
Description: Molar anchorage (non-implant)
Study: 15083355
Drug: Postoperative morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative morphine sulfate plus lidocaine administered as a local spray
Study: 8709630
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy according to NOPHO AML protocols
Study: 8709630
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow transplantation (BMT) without prior chemotherapy
Study: 6189439
Drug: Calcitonin, blocking
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcitonin, blocking agents, intravenous clomipramine, periarterial injections of local anaesthetics, local or general corticotherapy, physiotherapy, kinesitherapy
Study: 31370896
Drug: Sodium citrate
Normalized name: Sodium Citrate
DrugBank: Sodium nitrate (DB15952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium citrate (SC - 0.5 g.kg‐1BM in capsules of 500 mg)
Study: 28381584
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) with aspirin + a P2Y12 inhibitor
Study: 26390721
Drug: Chemotherapy (non-auto-HSCT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (non-auto-HSCT group)
Study: 23958795
Drug: 0.8 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 mg/kg of alcohol
Study: 9814091
Drug: tenoxicam 20
Normalized name: tenoxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: tenoxicam 20 mg daily for six weeks
Study: 9814091
Drug: piroxicam 20
Normalized name: piroxicam 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: piroxicam 20 mg daily for six weeks
Study: 7542109
Drug: Finasteride 5
Normalized name: finasteride 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finasteride 5 mg daily for 6 months
Study: 1087383
Drug: L‐5‐hydroxytryptophan (alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐5‐hydroxytryptophan (alone or in combination with carbidopa)
Study: 30572162
Drug: Computer-assisted cognitive-behavior
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer-assisted cognitive-behavior therapy (CCBT)
Study: 26464212
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment (79% prescribed insulin, mean total daily dose 0.41 units/kg)
Study: 26464212
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (62% prescribed insulin, mean total daily dose 0.30 units/kg)
Study: 23011728
Drug: Prandial insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prandial insulin
Study: 26464212
Drug: Insulin dose
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin dose after adjustment for covariates
Study: 23542800
Drug: Protective ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Protective ventilation strategy (tidal volume of 7 ml/kg ideal body weight, 10 cm H2O positive end-expiratory pressure, and recruitment maneuvers)
Study: 23542800
Drug: Standard ventilation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard ventilation strategy (tidal volume of 9 ml/kg ideal body weight and zero-positive end-expiratory pressure)
Study: 19874247
Drug: Antidepressants and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressants and hormonal supplements
Study: 17085763
Drug: Integrated care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrated care treatment model
Study: 17085763
Drug: Treatment initiation
Normalized name: Otezla 10mg-20mg 28-Day Treatment Initiation Pack Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment initiation
Study: 17085763
Drug: Predictors of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Predictors of research adherence and treatment initiation
Study: 14727010
Drug: L‐T4 (n=31)
Approvals — FDA: no, EMA: no, PMDA: no
Description: L‐T4 (n=31)
Study: 9466067
Drug: Warfarin continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warfarin continued (17 patients, 85%)
Study: 9466067
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (non-warfarin)
Study: 3279916
Drug: 200 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg/kg phospholipid given intratracheally (treatment group)
Study: 31487797
Drug: Kefir (180
Approvals — FDA: no, EMA: no, PMDA: no
Description: Kefir (180 mL/day)
Study: 26025412
Drug: Contraceptive pill
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Contraceptive pill + flare-up GnRH‐agonist protocol (P2)
Study: 26025412
Drug: GnRH‐antagonist protocol
Approvals — FDA: no, EMA: no, PMDA: no
Description: GnRH‐antagonist protocol (P3)
Study: 24273972
Drug: Nitroglycerine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerine (1 mg sublingual administration)
Study: 19484202
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of two or more drugs
Study: 8626358
Drug: Nefazodone (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nefazodone (200 to 600 mg/day)
Study: 8626358
Drug: Imipramine (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imipramine (100 to 300 mg/day)
Study: 8626358
Drug: Placebo (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (2 to 6 capsules/day)
Study: 1627372
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interleukin-2 (300 micrograms/m2)
Study: 1627372
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant interleukin-2 (300 micrograms/m2)
Study: 1627372
Drug: Subcutaneous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous recombinant interleukin-2
Study: 1627372
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant interleukin-2
Study: 31234642
Drug: Eptinezumab 10
Normalized name: EPTINEZUMAB 100 mg in 1 mL INTRAVENOUS INJECTION [Vyepti]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eptinezumab 10 mg
Study: 30345457
Drug: Crisaborole ointment
Normalized name: Crisaborole Ointment
DrugBank: Crisaborole (DB05219)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Crisaborole ointment
Study: 22465890
Drug: Intravenous erythropoietin
Normalized name: Erythropoietin
DrugBank: Erythropoietin (DB00016)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous erythropoietin (20,000 unit/24 hours) for 5 consecutive days along with intravenous methyl prednisolone (1000 mg/24 hours)
Study: 22465890
Drug: Intravenous methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous methyl prednisolone (1000 mg/24 hours) and placebo
Study: 20526703
Drug: CLD 100
Normalized name: CldAdo
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLD 100 mg IM weekly for 12 months
Study: 20526703
Drug: CLD 200
Normalized name: CldAdo
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: CLD 200 mg IM every 2 weeks for 12 months
Study: 9220520
Drug: No maintenance
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: No maintenance therapy (Control)
Study: 9220520
Drug: Serum ECP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ECP > or = 16 micrograms/L
Study: 9220520
Drug: Serum ECP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ECP < 16 micrograms/L
Study: 9220520
Drug: Serum ECP
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Serum ECP > or = 8 micrograms/L
Study: 8427515
Drug: 600 mg/day
Normalized name: Rebetron, single dose 600 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/day tiludronate for five days
Study: 8427515
Drug: 800 mg/day
Normalized name: RibaTab 800 mg/day Compliance Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg/day tiludronate for five days
Study: 8427515
Drug: 1200 mg/day
Normalized name: Rebetron, single dose 1200 mg/day oral and injectable kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg/day tiludronate for five days
Study: 3113413
Drug: Simple electrolyte
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple electrolyte solutions or isocaloric parenteral regimes without fat emulsion
Study: 3113413
Drug: Dextrose or
Normalized name: Dextrose Oral Liquid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dextrose or amino acid solutions
Study: 29177979
Drug: Diode laser
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diode laser and topical treatment
Study: 29177979
Drug: Topical treatment
Normalized name: Hongo Killer Treatment Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical treatment only
Study: 16188911
Drug: 3-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1) with a dairy breakfast
Study: 16188911
Drug: 3-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-h intravenous infusion of saline with a dairy breakfast
Study: 16188911
Drug: 3-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-h intravenous infusion of glucagon-like peptide-1 (GLP-1)
Study: 16188911
Drug: 3-h intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-h intravenous infusion of saline
Study: 12657991
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg of tropisetron
Study: 10747265
Drug: Oral piroxicam
Normalized name: Piroxicam
DrugBank: Piroxicam (DB00554)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral piroxicam 1 mg/kg/day
Study: 10747265
Drug: Soluble aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soluble aspirin 100 mg/kg/day taken four-hourly
Study: 8936562
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) administered immediately after fluoxetine
Study: 8936562
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) administered 2 hours after fluoxetine
Study: 8936562
Drug: Activated charcoal
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Activated charcoal (25 g) administered 4 hours after fluoxetine
Study: 8936562
Drug: Fluoxetine on
Normalized name: Fluoxetine only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine on an empty stomach with water only
Study: 1539484
Drug: labetalol 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: labetalol 0.5 mg.kg‐1 i.v. in addition to isoflurane
Study: 23635049
Drug: Penicillin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Penicillin (250 mg twice a day for 12 months)
Study: 19268929
Drug: Metformin 500
Normalized name: metformin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin 500 mg twice a day (group A, 15 subjects)
Study: 16789979
Drug: Thyroxine treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroxine treatment for 1 year
Study: 14510745
Drug: Gastric-retentive floating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gastric-retentive floating tablet administered with three different solid meals
Study: 10868321
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with varying electrode placement and stimulus intensity
Study: 10868321
Drug: Electroconvulsive therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroconvulsive therapy (ECT) with right unilateral (RUL) electrode placement
Study: 9124826
Drug: Cefodizime (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefodizime (2,000 mg as an intravenous bolus; n = 6)
Study: 9124826
Drug: Cefpirome (2,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefpirome (2,000 mg as an intravenous bolus; n = 6)
Study: 9124826
Drug: Fleroxacin (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fleroxacin (400 mg orally; n = 6)
Study: 9124826
Drug: Dirithromycin (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dirithromycin (250 mg orally; n = 4)
Study: 1389343
Drug: dentin bonding
Normalized name: SKIN BOND
Approvals — FDA: no, EMA: no, PMDA: no
Description: dentin bonding agent
Study: 3926504
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of insulin (0.67 nmol kg‐1 body weight)
Study: 3926504
Drug: Control (blood
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (blood taken before insulin administration)
Study: 31424389
Drug: No psychotropic
Approvals — FDA: no, EMA: no, PMDA: no
Description: No psychotropic drugs (NO)
Study: 29275871
Drug: Rivaroxaban without
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban without aspirin
Study: 27766505
Drug: Oral supplement
Normalized name: Healios Oral Supplement Unflavored
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral supplement of properly balanced omega-3 and omega-6 fatty acids
Study: 27766505
Drug: Topical cyclosporine
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical cyclosporine treatment
Study: 27766505
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of omega-3 and omega-6 fatty acids with topical cyclosporine
Study: 23959782
Drug: Tea with
Normalized name: MENTHOL 4.1 mg ORAL LOZENGE [SUGAR FREE GREEN TEA WITH ECHINACEA COUGH SUPPRESSANT THROAT DROPS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tea with milk (250 ml black tea plus 50 ml of full fat milk)
Study: 8617188
Drug: Black tea
Normalized name: black tea
Approvals — FDA: no, EMA: no, PMDA: no
Description: Black tea (300 ml)
Study: 22294639
Drug: GO‐ON (MW
Approvals — FDA: no, EMA: no, PMDA: no
Description: GO‐ON (MW 800‐1500 kD, 25 mg/2.5 ml)
Study: 22294639
Drug: Hyalgan (MW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyalgan (MW 500‐730 kD, 20 mg/2 ml)
Study: 18636279
Drug: Epidural bupivacaine/morphine/clonidine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epidural bupivacaine/morphine/clonidine
Study: 12610037
Drug: Vardenafil (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vardenafil (both doses)
Study: 1780819
Drug: Arnica 10(‐30)
Normalized name: Arnica
DrugBank: Arnica montana flower (DB14343)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arnica 10(‐30) five pills twice daily for five days, starting the day before the event.
Study: 17519400
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emtricitabine qd for 7 days
Study: 17519400
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg tenofovir disoproxil fumarate qd for 7 days
Study: 17519400
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg emtricitabine plus 300 mg tenofovir disoproxil fumarate qd for 7 days
Study: 16236942
Drug: Dexamethasone (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (1 mg/kg before anesthesia induction and 0.5 mg/kg after 8 h; n = 10)
Study: 10202874
Drug: Pyridostigmine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyridostigmine (60 mg orally twice daily from the first day of COH until the day of hCG injection)
Study: 7750319
Drug: Weight loss
Normalized name: HERBAL WEIGHT LOSS AID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weight loss combined with sleeping on side and nasal spray
Study: 2316014
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (6 g daily for three months)
Study: 2316014
Drug: Placebo (6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (6 g corn oil for three months)
Study: 6270966
Drug: Adjuvant local
Normalized name: RECTAL,LOCAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvant local radiation therapy
Study: 6270966
Drug: Cyclic treatment
Normalized name: cyclic AMP
DrugBank: Cyclic adenosine monophosphate (DB02527)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclic treatment with 5‐Fluorouracil, Methotrexate and Chlorambucil
Study: 25791613
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (2 mg/24 h on days 1 to 3, followed by 4 mg/24 h on days 4 to 6)
Study: 25791613
Drug: Rotigotine transdermal
Normalized name: Rotigotine Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rotigotine transdermal patch (2 mg/24 h and 4 mg/24 h)
Study: 10586011
Drug: Systemic prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Systemic prednisolone mixture 2 mg/kg daily for 5 days
Study: 1536632
Drug: Control (symptomatic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (symptomatic drugs only)
Study: 1871492
Drug: Immunotherapy by
Normalized name: By Ache
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immunotherapy by oral route
Study: 31227397
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of tranexamic acid (TXA) 10 mL (100 mg/mL)
Study: 31227397
Drug: Intra-articular injection
Normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular injection of tranexamic acid (TXA)